| Pain in female genitalia on intercourse
Intrarosa vs Osphena
Side-by-side clinical, coverage, and cost comparison for pain in female genitalia on intercourse.Deep comparison between: Intrarosa vs Osphena with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOsphena has a higher rate of injection site reactions vs Intrarosa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Osphena but not Intrarosa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Intrarosa
Osphena
At A Glance
Vaginal insert
Once daily
Endogenous steroid
Oral
Daily
Estrogen receptor agonist/antagonist
Indications
- Pain in female genitalia on intercourse
- Pain in female genitalia on intercourse
- Postmenopausal atrophic vaginitis
Dosing
Pain in female genitalia on intercourse One vaginal insert once daily at bedtime using the provided applicator.
Pain in female genitalia on intercourse, Postmenopausal atrophic vaginitis One 60 mg tablet taken orally with food once daily.
Contraindications
- Undiagnosed, persistent, or recurring abnormal genital bleeding
- Undiagnosed abnormal genital bleeding
- Estrogen-dependent neoplasia
- Active DVT, PE, or history of these conditions
- Active arterial thromboembolic disease (e.g., stroke, MI) or history of these conditions
- Hypersensitivity (e.g., angioedema, urticaria, rash, pruritus) to ospemifene or any ingredient
- Pregnancy or potential pregnancy
Adverse Reactions
Most common (>=2%) Vaginal discharge, abnormal Pap smear
Most common (>=1%) Hot flush, vaginal discharge, muscle spasms, hyperhidrosis
Serious Thromboembolic stroke, hemorrhagic stroke, DVT, malignant neoplasms
Postmarketing Endometrial hyperplasia, endometrial cancer, hypersensitivity, angioedema, headache, deep vein thrombosis, pulmonary embolism, rash, pruritus, urticaria
Pharmacology
Prasterone is an inactive endogenous steroid that is converted into active androgens and/or estrogens via human steroidogenic enzymes; its mechanism of action in postmenopausal women with vulvar and vaginal atrophy is not fully established.
Ospemifene is an estrogen receptor agonist/antagonist with tissue-selective effects, activating estrogenic pathways in some tissues (agonism) and blocking them in others (antagonism).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Intrarosa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (5/12) · Qty limit (9/12)
Osphena
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Intrarosa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Osphena
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Intrarosa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Osphena
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Intrarosa.
No savings programs available for Osphena.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IntrarosaView full Intrarosa profile
OsphenaView full Osphena profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.